198 related articles for article (PubMed ID: 28970075)
1. Giant cell tumor of bone under Denosumab treatment.
Wendling D; Guillot X; Sondag M; Chaigneau L; Aubry S; Prati C
Joint Bone Spine; 2018 Jul; 85(4):491. PubMed ID: 28970075
[No Abstract] [Full Text] [Related]
2. [Clinical, radiologic and pathologic features of giant cell tumor of bone treated with denosumab].
Gong LH; Liu WF; Ding Y; Zhang W; Yang YK; Yu F; Wong GQ; Huang XY; Niu XH
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):449-454. PubMed ID: 29886590
[No Abstract] [Full Text] [Related]
3. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
Sørensen AL; Hansen RL; Jørgensen PH
Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
[TBL] [Abstract][Full Text] [Related]
4. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery.
von Borstel D; A Taguibao R; A Strle N; E Burns J
Skeletal Radiol; 2017 Apr; 46(4):571-578. PubMed ID: 28188337
[TBL] [Abstract][Full Text] [Related]
5. Response evaluation of giant-cell tumor of bone treated by denosumab: Histogram and texture analysis of CT images.
Yi J; Lee YH; Kim SK; Kim SH; Song HT; Shin KH; Suh JS
J Orthop Sci; 2018 May; 23(3):570-577. PubMed ID: 29429890
[TBL] [Abstract][Full Text] [Related]
6. Metaphyseal sclerosis in a child with a giant cell tumour treated with denosumab.
Szymczuk V; Boyce A; Merchant N
Lancet; 2023 Jul; 402(10397):e4. PubMed ID: 37453752
[No Abstract] [Full Text] [Related]
7. Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone.
Marques P; Appelman-Dijkstra NM; Gelderblom H; Kruit MC; van Furth WR; Pereira AM; Biermasz NR
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):348. PubMed ID: 32059785
[No Abstract] [Full Text] [Related]
8. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
[TBL] [Abstract][Full Text] [Related]
9. Denosumab, a Potential Alternative to the Surgical Treatment of Distal Radius Giant Cell Tumor of Bone: Case Report.
Park MJ; Ganjoo KN; Ladd AL
J Hand Surg Am; 2015 Aug; 40(8):1620-4. PubMed ID: 25935517
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
11. Denosumab does not decrease the risk of lung metastases from bone giant cell tumour.
Tsukamoto S; Mavrogenis AF; Leone G; Righi A; Akahane M; Tanzi P; Kido A; Honoki K; Tanaka Y; Donati DM; Errani C
Int Orthop; 2019 Feb; 43(2):483-489. PubMed ID: 30099641
[TBL] [Abstract][Full Text] [Related]
12. [Ⅱ. Success and Limitations of Denosumab for Giant Cell Tumor of Bone].
Asano N
Gan To Kagaku Ryoho; 2021 Mar; 48(3):346-350. PubMed ID: 33790155
[No Abstract] [Full Text] [Related]
13. Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort.
Boye K; Jebsen NL; Zaikova O; Knobel H; Løndalen AM; Trovik CS; Monge OR; Hall KS
Acta Oncol; 2017 Mar; 56(3):479-483. PubMed ID: 28105885
[TBL] [Abstract][Full Text] [Related]
14. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
Reddy K; Ramirez L; Kukreja K; Venkatramani R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
[TBL] [Abstract][Full Text] [Related]
15. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
[TBL] [Abstract][Full Text] [Related]
16. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
Roitman PD; Jauk F; Farfalli GL; Albergo JI; Aponte-Tinao LA
Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
[TBL] [Abstract][Full Text] [Related]
17. Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone.
Engellau J; Seeger L; Grimer R; Henshaw R; Gelderblom H; Choy E; Chawla S; Reichardt P; O'Neal M; Feng A; Jacobs I; Roberts ZJ; Braun A; Bach BA
World J Surg Oncol; 2018 Sep; 16(1):191. PubMed ID: 30231890
[TBL] [Abstract][Full Text] [Related]
18. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
19. Recurrent giant cell tumour of the maxillary sinus and pterygoid process treated with denosumab.
Rosa D; Dias RB; Salvador JC; Borges A
BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30196254
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of the molecular penotypes and histopathological features of giant cell tumor of bone with denosumab treatment].
Gong LH; Dong RF; Zhang W; Sun XQ; Zhang M; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2021 Jan; 50(1):60-62. PubMed ID: 33396989
[No Abstract] [Full Text] [Related]
[Next] [New Search]
